Calcium Channel Blocker Market by Drug class (Dihydropyridine and Non-Dihydropyridine) for Hypertension, Angina Pectoris, Pregnancy, Obesity and Other - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022

January 2017 | 110 pages | ID: C6EC9FBD602EN
Zion Market Research

Abstracts

The report covers forecast and analysis for the calcium channel blocker market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based on revenue (USD million). The study includes drivers and restraints for the Calcium channel blocker market along with the impact they have on the demand in the forecast period. Additionally, the report includes the study of opportunities available in the calcium channel blocker market on a global level.

In order to give the users a comprehensive view on the calcium channel blocker market and to understand the competitive landscape in the market, an analysis of Porters Five Forces model for the calcium channel blocker market has also been included. The study encompasses a market attractiveness analysis, wherein drug class segments are benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view on the calcium channel blocker market by segmenting the market based on drug class and application. Drug Class and application have been analyzed based on present and future trends and the market is estimated from 2016 to 2022. The regional segmentation includes the current and forecast demand for the regions like North America, Europe, Asia-Pacific, Latin America and the Middle East Africa. This segmentation includes demand for individual applications in all the regions.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global calcium channel blocker which include Pfizer Inc., AstraZeneca Plc., Bayer Healthcare LLC., GlaxoSmithKline Plc., Sanofi S.A., Johnson Johnson, Abcam, AbMole Bioscience, and Clearsynth.

This report segments the global calcium channel blocker as follows:

Global Calcium Channel Blocker: Drug Type Segment Analysis

Dihydropyridine
Amlodipine
Cilnidipine
Felodipine
Isradipine
Nicardipine
Nisoldipine
Nifedipine
Others
Non-Dihydropyridine
Diltiazem
Verapamil

Global Calcium Channel Blocker: Application Type Segment Analysis

Angina pectoris
Hypertension
Pregnancy
Anti-obesity
Other

Global Calcium Channel Blocker: Regional Segment Analysis

North America
U.S.
Europe
Asia Pacific
China
Japan
Latin America
Brazil
Middle East and Africa

Contents

CHAPTER 1. INTRODUCTION

1.1. Report Description And Scope
1.2. Research Scope
1.3. Research Methodology
  1.3.1. Market Research Process
  1.3.2. Market Research Methodology

CHAPTER 2. EXECUTIVE SUMMARY

2.1. Global Calcium Channel Blocker Market, 2016 - 2022 (USD Million)
2.2. Global Calcium Channel Blocker Market: Snapshot

CHAPTER 3. CALCIUM CHANNEL BLOCKER MARKET DYNAMICS

3.1. Introduction
3.2. Value Chain Analysis
3.3. Market Drivers
  3.3.1. Global Calcium Channel Blocker Market Drivers: Impact Analysis
  3.3.2. Rising prevalence of Hypertension.
  3.3.3. Growth percentage of Obesity.
3.4. Market Restraints
  3.4.1. Global Calcium Channel Blocker Market Restraints: Impact Analysis
  3.4.2. Adverse Effect of Drug.
3.5. Opportunities
  3.5.1. Combination Therapy of CCB Drugs
3.6. Porters Five Forces Analysis
  3.6.1. Bargaining Power Of Suppliers
  3.6.2. Bargaining Power Of Buyers
  3.6.3. Threat From New Entrants
  3.6.4. Threat From New Substitutes
  3.6.5. Degree Of Competition
3.7. Market Attractiveness Analysis
  3.7.1. Market Attractiveness Analysis, By Drug Class Segment
  3.7.2. Market Attractiveness Analysis, By Application Segment
  3.7.3. Market Attractiveness Analysis, By Regional Segment

CHAPTER 4. GLOBAL CALCIUM CHANNEL BLOCKER MARKET COMPETITIVE LANDSCAPE

4.1. Company Market Share, 2016 (Subject To Data Availability)
4.2. Strategic Development
  4.2.1. Acquisitions Mergers
  4.2.2. New Product Launch
  4.2.3. Agreements, Partnerships, Collaborations And Joint Ventures
  4.2.4. Research And Development, Product And Regional Expansion
4.3. Product Portfolio

CHAPTER 5. GLOBAL CALCIUM CHANNEL BLOCKER MARKET DRUG CLASS SEGMENT ANALYSIS

5.1. Global Calcium Channel Blocker Market: Drug Class Segment Overview
  5.1.1. Global Calcium Channel Blocker Market Revenue Share, By Drug Class Segment, 2016 And 2022
5.2. Dihydropyridine
  5.2.1. Global Dihydropyridine Market, 2016 2022 (USD Million)
  5.2.2. Amlodipine
    5.2.2.1. Calcium Channel Blocker Market Revenue for Amlodipine , 2016 2022 (USD Million)
  5.2.3. Cilnidipine
    5.2.3.1. Calcium Channel Blocker Market Revenue for Cilnidipine , 2016 2022 (USD Million)
  5.2.4. Felodipine
    5.2.4.1. Calcium Channel Blocker Market Revenue for Felodipine , 2016 2022 (USD Million)
  5.2.5. Isradipine
    5.2.5.1. Calcium Channel Blocker Market Revenue for Isradipine , 2016 2022 (USD Million)
  5.2.6. Nicardipine
    5.2.6.1. Calcium Channel Blocker Market Revenue for Nicardipine , 2016 2022 (USD Million)
  5.2.7. Nisoldipine
    5.2.7.1. Calcium Channel Blocker Market Revenue for Nisoldipine , 2016 2022 (USD Million)
  5.2.8. Nifedipine
    5.2.8.1. Calcium Channel Blocker Market Revenue for Nifedipine , 2016 2022 (USD Million)
  5.2.9. Others
    5.2.9.1. Calcium Channel Blocker Market Revenue for Others , 2016 2022 (USD Million)
5.3. Non-Dihydropyridine
  5.3.1. Global Non-Dihydropyridine Market, 2016 2022 (USD Million)
  5.3.2. Diltiazem
    5.3.2.1. Calcium Channel Blocker Market Revenue for Diltiazem , 2016 2022 (USD Million)
  5.3.3. Verapamil
    5.3.3.1. Calcium Channel Blocker Market Revenue for Verapamil , 2016 2022 (USD Million)

CHAPTER 6. GLOBAL CALCIUM CHANNEL BLOCKER MARKET APPLICATION SEGMENT ANALYSIS

6.1. Global Calcium Channel Blocker Market: Application Segment Overview
  6.1.1. Global Calcium Channel Blocker Market Revenue Share, By Application Segment, 2016 And 2022
6.2. Angina Pectoris
  6.2.1. Global Calcium Channel Blocker Market For Angina Pectoris, 2016 2022 (USD Million)
6.3. Hypertension
  6.3.1. Global Calcium Channel Blocker Market For Hypertension, 2016 2022 (USD Million)
6.4. Pregnancy
  6.4.1. Global Calcium Channel Blocker Market For Pregnancy, 2016 2022 (USD Million)
6.5. Obesity
  6.5.1. Global Calcium Channel Blocker Market For Obesity, 2016 2022 (USD Million)
6.6. Others
  6.6.1. Global Calcium Channel Blocker Market For Others, 2016 2022 (USD Million)

CHAPTER 7. GLOBAL CALCIUM CHANNEL BLOCKER MARKET REGIONAL SEGMENT ANALYSIS

7.1. Global Calcium Channel Blocker Market: Regional Overview
  7.1.1. Global Calcium Channel Blocker Market Revenue Share, By Region, 2016 And 2022
7.2. North America
  7.2.1. North America Calcium Channel Blocker Market Revenue, By Drug Class , 2016 2022 , (USD Million)
  7.2.2. North America Calcium Channel Blocker Market Revenue, By Application, 2016 2022 , (USD Million)
7.3. Europe
  7.3.1. Europe Calcium Channel Blocker Market Revenue, By Drug Class , 2016 2022 (USD Million)
  7.3.2. Europe Calcium Channel Blocker Market Revenue, By Application, 2016 2022 (USD Million)
7.4. Asia Pacific
  7.4.1. Asia Pacific Calcium Channel Blocker Market Revenue, By Drug Class , 2016 2022 (USD Million)
  7.4.2. Asia Pacific Calcium Channel Blocker Market Revenue, By Application, 2016 2022 (USD Million)
7.5. Latin America
  7.5.1. Latin America Calcium Channel Blocker Market Revenue, By Drug Class , 2016 2022 (USD Million)
  7.5.2. Latin America Calcium Channel Blocker Market Revenue, By Application, 2016 2022 (USD Million)
7.6. Middle East And Africa
  7.6.1. Middle East And Africa Calcium Channel Blocker Market Revenue, By Drug Class , 2016 2022 (USD Million)
  7.6.2. Middle East And Africa Calcium Channel Blocker Market Revenue, By Application, 2016 2022 (USD Million)

CHAPTER 8. COMPANY PROFILE

8.1. Pfizer Inc.,
  8.1.1. Overview
  8.1.2. Financials
  8.1.3. Product Portfolio
  8.1.4. Business Strategy
  8.1.5. Recent Developments
8.2. AstraZeneca plc.,
  8.2.1. Overview
  8.2.2. Financials
  8.2.3. Product Portfolio
  8.2.4. Business Strategy
  8.2.5. Recent Developments
8.3. Bayer Healthcare LLC.
  8.3.1. Overview
  8.3.2. Financials
  8.3.3. Product Portfolio
  8.3.4. Business Strategy
  8.3.5. Recent Developments
8.4. GlaxoSmithKline plc
  8.4.1. Overview
  8.4.2. Financials
  8.4.3. Product Portfolio
  8.4.4. Business Strategy
  8.4.5. Recent Developments
8.5. Sanofi S.A.
  8.5.1. Overview
  8.5.2. Financials
  8.5.3. Product Portfolio
  8.5.4. Business Strategy
  8.5.5. Recent Developments
8.6. Johnson Johnson
  8.6.1. Overview
  8.6.2. Financials
  8.6.3. Product Portfolio
  8.6.4. Business Strategy
  8.6.5. Recent Developments
8.7. Abcam
  8.7.1. Overview
  8.7.2. Financials
  8.7.3. Product Portfolio
  8.7.4. Business Strategy
  8.7.5. Recent Developments
8.8. AbMole Bioscience
  8.8.1. Overview
  8.8.2. Financials
  8.8.3. Product Portfolio
  8.8.4. Business Strategy
  8.8.5. Recent Developments
8.9. Clearsynth
  8.9.1. Overview
  8.9.2. Financials
  8.9.3. Product Portfolio
  8.9.4. Business Strategy
  8.9.5. Recent Developments